drugset / Trial / NCT00470093
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
Phase 0
Terminated
3 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa together with interleukin-6 works in treating patients with recurrent multiple myeloma.
Timeline
- Start
- 2007-10
- Primary completion
- 2010-01
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon-α | Protein / enzyme biologic | 3e+06 iu | Subcutaneous |
| Subject | Pregabalin | Small molecule | 2.5 ug/kg | Subcutaneous |